583 related articles for article (PubMed ID: 30506519)
1. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).
Kato K; Satoh T; Muro K; Yoshikawa T; Tamura T; Hamamoto Y; Chin K; Minashi K; Tsuda M; Yamaguchi K; Machida N; Esaki T; Goto M; Komatsu Y; Nakajima TE; Sugimoto N; Yoshida K; Oki E; Nishina T; Tsuji A; Fujii H; Kunieda K; Saitoh S; Omuro Y; Azuma M; Iwamoto Y; Taku K; Fushida S; Chen LT; Kang YK; Boku N
Gastric Cancer; 2019 Mar; 22(2):344-354. PubMed ID: 30506519
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Chen LT; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Sameshima H; Kang YK; Boku N
Gastric Cancer; 2020 May; 23(3):510-519. PubMed ID: 31863227
[TBL] [Abstract][Full Text] [Related]
5. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
Satoh T; Kang YK; Chao Y; Ryu MH; Kato K; Cheol Chung H; Chen JS; Muro K; Ki Kang W; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Tanimoto M; Chen LT; Boku N
Gastric Cancer; 2020 Jan; 23(1):143-153. PubMed ID: 31087200
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
Xu RH; Zhang Y; Pan H; Feng J; Zhang T; Liu T; Qin Y; Qin S; Yin X; Liu B; Ba Y; Yang N; Voon PJ; Tanasanvimon S; Zhou C; Zhang WL; Shen L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Nishiyama T; Chen LT; Kang YK
Gastric Cancer; 2021 Jul; 24(4):946-958. PubMed ID: 33743112
[TBL] [Abstract][Full Text] [Related]
9. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
Yoon HH; Bendell JC; Braiteh FS; Firdaus I; Philip PA; Cohn AL; Lewis N; Anderson DM; Arrowsmith E; Schwartz JD; Gao L; Hsu Y; Xu Y; Ferry D; Alberts SR; Wainberg ZA
Ann Oncol; 2016 Dec; 27(12):2196-2203. PubMed ID: 27765757
[TBL] [Abstract][Full Text] [Related]
10. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
Chau I; Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Sanchez T; Maglinte GA; Laurie M; Abraham P; Patel D; Shangguan T
Gastric Cancer; 2020 Jan; 23(1):133-141. PubMed ID: 31549264
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS; Shitara K; Di Bartolomeo M; Lonardi S; Al-Batran SE; Van Cutsem E; Ilson DH; Alsina M; Chau I; Lacy J; Ducreux M; Mendez GA; Alavez AM; Takahari D; Mansoor W; Enzinger PC; Gorbounova V; Wainberg ZA; Hegewisch-Becker S; Ferry D; Lin J; Carlesi R; Das M; Shah MA;
Lancet Oncol; 2019 Mar; 20(3):420-435. PubMed ID: 30718072
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme.
Soni M; Kiff C; Carroll R; Stein D; Saragoussi D; Nassar A; Maisey N; Tyas D
Future Oncol; 2021 Aug; 17(24):3163-3174. PubMed ID: 34098737
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses.
Ohyama C; Kojima T; Kondo T; Naya Y; Inoue T; Tomita Y; Eto M; Hisasue S; Uemura H; Obara W; Kikuchi E; Sharma P; Galsky MD; Siefker-Radtke A; Grossfeld G; Collette S; Gooden K; Kimura G
Int J Clin Oncol; 2019 Sep; 24(9):1089-1098. PubMed ID: 31218529
[TBL] [Abstract][Full Text] [Related]
16. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY; Bendell J; Calvo E; Kim JW; Ascierto PA; Sharma P; Ott PA; Peltola K; Jaeger D; Evans J; de Braud F; Chau I; Harbison CT; Dorange C; Tschaika M; Le DT
J Clin Oncol; 2018 Oct; 36(28):2836-2844. PubMed ID: 30110194
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
[TBL] [Abstract][Full Text] [Related]
19. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
